Clinicopathological characteristics in relation to Ki-67 index
| Ki-67 index | p Value* | |||
|---|---|---|---|---|
| Low | Intermediate | High | ||
| The p values were assessed by the χ2 test. | ||||
| NHG, Nottingham histological grade. | ||||
| Total number | 194 (%) | 118 (%) | 118 (%) | |
| Randomisation | 0.12 | |||
| Tamoxifen | 85 (43.8) | 66 (55.9) | 57 (48.3) | |
| Control | 109 (56.2) | 52 (44.1) | 61(51.7) | |
| Age | 0.38 | |||
| <40 years | 32 (16.5) | 24 (20.3) | 26 (22.0) | |
| 40–49 years | 126 (64.9) | 79 (66.9) | 78 (66.1) | |
| 50–59 years | 36 (18.6) | 15 12.7) | 14 (11.8) | |
| Tumour size | 0.01 | |||
| 0–10 mm | 14 (7.2) | 8 (6.8) | 6 (5.1) | |
| 11–20 mm | 68 (35.0) | 35 (29.7) | 21 (17.8) | |
| 21+ mm | 112 (57.7) | 74 (62.7) | 91 (77.1) | |
| Lymph node status | 0.56 | |||
| 0 | 52 (26.8) | 31 | 43 | |
| 1–3 | 98 (50.5) | 57 | 30 | |
| 4 | 43 (22.2) | 50 | 25 | |
| Not registered | 1 (0.05) | |||
| NHG | <0.001 | |||
| I | 44 (22.7) | 6 (5.1) | 0 (0) | |
| II | 104 (53.6) | 48 (40.7) | 19 (16.1) | |
| III | 42 (21.6) | 58 (49.1) | 94 (79.7) | |
| Not evaluated | 4 (2.1) | 6 (5.1) | 5 (4.2) | |
| Mitotic index | ||||
| 1 | 99 (51.0) | 27 (22.9) | 7 (5.9) | <0.001 |
| 2 | 63 (32.5) | 49 (41.5) | 30 (25.4) | |
| 3 | 28 (14.4) | 36 (30.5) | 76 (64.4) | |
| Not evaluated | 4 (2.1) | 6 (5.1) | 5 (4.2) | |
| Oestrogen receptor | <0.001 | |||
| Negative | 33 (17.0) | 34 (28.8) | 71 (60.2) | |
| Positive | 155 (79.9) | 81 (68.6) | 44 (37.3) | |
| Not evaluated | 6 (3.1) | 3 (2.5) | 3 (2.5) | |
| Progesterone receptor | <0.001 | |||
| Negative | 35 (18.0) | 41 (34.7) | 76 (64.4) | |
| Positive | 147 (75.8) | 68 (57.6) | 37 (31.3) | |
| Not evaluated | 12 (6.2) | 9 (7.6) | 5 (4.2) | |